23andMe: the early bird of web based biotech startups

23andMe is a biotech focused web startup based in Mountain View, California (yes, the Googleplex neighbourhood) self-defined as “an early stage startup developing tools and producing content to help people make sense of their genetic information. Our goal is to take advantage of new genotyping technologies and help consumers explore their genetics, informed by cutting edge science. Genome deciphering technologies have reached affordable levels, allowing consumer access. For the individual, such information will provide personal insight into ancestry, genealogy and health. For society, the collection of genotypic and phenotypic information on a large scale will provide scientists with novel avenues for research.”
Briefly, they are concentrating on the enormous genomics data we already have to analyze them for customers. They are probably right, because in biotech, genomics could be the first field that has enough results, easy measurement methods (a little blood or biopsies), infotech background and enough commercial demand to make the business profitable within 1-2 years. Unfortunately, regenerative medicine and the stem cells frontier are not in this position yet. The next business step could be monetizing data from proteomics, transcriptomics. With the promising combination of computer science, biology and informatics 23andMe is an early bird of a biotech-based web domain, because there will be times when all your genes, RNAs, peptides (and in my opinion: cells and tissues) will be taken into account by your initiative to know your future prospects, and a web-based service is a proper choice for managing all of your biodata. Security problems will emerge, of course.